{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:53Z","timestamp":1792218353025,"version":"4.4.0"},"reference-count":99,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach designed to bind antigens on malignant plasma cells and cytotoxic immune effector cells. Early-phase clinical trials targeting B-cell maturation antigen (BCMA), GPRC5D, and FcRH5 have demonstrated a favorable safety profile, with mainly low-grade cytokine release syndrome, cytopenias, and infections. Although dose escalation is ongoing in several studies, early efficacy data show response rates in the most active dose cohorts between 61% and 83% with many deep responses; however, durability remains to be established. Further clinical trial data are eagerly anticipated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance:<\/jats:title><jats:p>Overall survival of triple-class refractory multiple myeloma remains poor. Bispecific antibodies are a novel immunotherapeutic modality with a favorable safety profile and impressive preliminary efficacy in heavily treated patients. Although more data are needed, bispecifics will likely become an integral part of the multiple myeloma treatment paradigm in the near future. Studies in earlier lines of therapy and in combination with other active anti\u2013multiple myeloma agents will help further define the role of bispecifics in multiple myeloma.<\/jats:p><\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-21-0028","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T14:22:30Z","timestamp":1629210150000},"page":"423-433","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Bispecific Antibodies in Multiple Myeloma: Present and Future"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9775-7127","authenticated-orcid":false,"given":"Guido","family":"Lancman","sequence":"first","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahniel L.","family":"Sastow","sequence":"additional","affiliation":[{"name":"2Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn J.","family":"Cho","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Parekh","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"1Tisch Cancer Insitute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2022060217155234300_bib1","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2022060217155234300_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"2022060217155234300_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"2022060217155234300_bib4","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res"},{"key":"2022060217155234300_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic Fc engineering\u2013modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"2022060217155234300_bib6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"2022060217155234300_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/protein\/gzx043","article-title":"Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells","volume":"30","author":"Gantke","year":"2017","journal-title":"Protein Eng Des Sel"},{"key":"2022060217155234300_bib8","article-title":"Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma [abstract]","volume-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29\u2013Apr 3; Atlanta, GA","author":"Draghi"},{"key":"2022060217155234300_bib9","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"2022060217155234300_bib10","article-title":"Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA\/CD16a bispecific antibody for the treatment of multiple myeloma [abstract]","volume-title":"Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27\u201328 and Jun 22\u201324","author":"Kakiuchi-Kiyota"},{"key":"2022060217155234300_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"2022060217155234300_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"2022060217155234300_bib13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA \u00d7 CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2022060217155234300_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"2022060217155234300_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022060217155234300_bib16","doi-asserted-by":"crossref","first-page":"v808","DOI":"10.1093\/annonc\/mdz269.038","article-title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","volume":"30","author":"Li","year":"2019","journal-title":"Ann Oncol"},{"key":"2022060217155234300_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"2022060217155234300_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2022060217155234300_bib19","first-page":"4463","volume":"134","author":"He","year":"2019","journal-title":"Preclinical characterization of an ANTI-CD38\/CD3 T cell-redirecting bispecific antibody"},{"key":"2022060217155234300_bib20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell\u2013redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2022060217155234300_bib21","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/j.clml.2019.09.202","article-title":"Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma","volume":"19","author":"Verkleij","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022060217155234300_bib22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2022060217155234300_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi 38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicities for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"key":"2022060217155234300_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"key":"2022060217155234300_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2022060217155234300_bib26","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"key":"2022060217155234300_bib27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"2022060217155234300_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2022060217155234300_bib29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"2022060217155234300_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2022060217155234300_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"2022060217155234300_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor\u2013like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"2022060217155234300_bib33","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.173.4.2245","article-title":"TNF family member B cell-activating factor (BAFF) receptor-dependent and-independent roles for BAFF in B cell physiology","volume":"173","author":"Sasaki","year":"2004","journal-title":"J Immunol"},{"key":"2022060217155234300_bib34","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","article-title":"Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells","volume":"178","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"2022060217155234300_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat Immunol"},{"key":"2022060217155234300_bib36","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022060217155234300_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/imt-2018-0199","article-title":"B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma","volume":"11","author":"Eckhert","year":"2019","journal-title":"Immunotherapy"},{"key":"2022060217155234300_bib38","volume-title":"Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM)","author":"Dispenzieri"},{"key":"2022060217155234300_bib39","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.145.8.2390","article-title":"Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation","volume":"145","author":"Funaro","year":"1990","journal-title":"J Immunol"},{"key":"2022060217155234300_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"2022060217155234300_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"2022060217155234300_bib42","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"key":"2022060217155234300_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r) evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"2022060217155234300_bib44","doi-asserted-by":"crossref","first-page":"e1279723","DOI":"10.1080\/23723556.2017.1279723","article-title":"Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer","volume":"4","author":"Crowell","year":"2017","journal-title":"Mol Cell Oncol"},{"key":"2022060217155234300_bib45","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jaci.2004.04.040","article-title":"Methodologic advancements in the study of airway smooth muscle","volume":"114","author":"Kotlikoff","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2022060217155234300_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2119\/molmed.2008.00108","article-title":"CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus","volume":"15","author":"Horenstein","year":"2009","journal-title":"Mol Med"},{"key":"2022060217155234300_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"2022060217155234300_bib48","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/IJG.0000000000000995","article-title":"Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma","volume":"27","author":"Lee","year":"2018","journal-title":"J Glaucoma"},{"key":"2022060217155234300_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajoc.2018.12.017","article-title":"Daratumumab-induced transient myopic shift","volume":"13","author":"Mavrommatis","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2022060217155234300_bib50","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"2022060217155234300_bib51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib52","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib53","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"2022060217155234300_bib56","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"2022060217155234300_bib57","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"key":"2022060217155234300_bib59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"2022060217155234300_bib60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"2022060217155234300_bib61","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2022060217155234300_bib62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/eji.200425886","article-title":"An extended family of Fc receptor relatives","volume":"35","author":"Davis","year":"2005","journal-title":"Eur J Immunol"},{"key":"2022060217155234300_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J Leukoc Biol"},{"key":"2022060217155234300_bib64","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia","volume":"18","author":"Polson","year":"2006","journal-title":"Int Immunol"},{"key":"2022060217155234300_bib65","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"2022060217155234300_bib66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"key":"2022060217155234300_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J"},{"key":"2022060217155234300_bib68","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022060217155234300_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139893","article-title":"Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136985","article-title":"Initial clinical activity and safety of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-133873","article-title":"A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib75","first-page":"S205","article-title":"Interim results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) 2+ 1 T-cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"295025","author":"Costa","year":"2020","journal-title":"EHA Library"},{"key":"2022060217155234300_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-133355","article-title":"Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Lesokhin","year":"2020","journal-title":"Blood"},{"key":"2022060217155234300_bib77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2022060217155234300_bib78","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"2022060217155234300_bib79","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/ajh.25428","article-title":"Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications","volume":"94","author":"Susanibar Adaniya","year":"2019","journal-title":"Am J Hematol"},{"key":"2022060217155234300_bib80","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2022060217155234300_bib81","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"2022060217155234300_bib82","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"2022060217155234300_bib83","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"2022060217155234300_bib84","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"2022060217155234300_bib85","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib86","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022060217155234300_bib87","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022060217155234300_bib88","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","article-title":"Genetics of multiple myeloma: another heterogeneity level?","volume":"125","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"2022060217155234300_bib89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"2022060217155234300_bib90","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib91","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib92","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"2022060217155234300_bib94","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022060217155234300_bib95","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022060217155234300_bib96","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"2022060217155234300_bib97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"2022060217155234300_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2022060217155234300_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/5\/423\/3098872\/423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/2\/5\/423\/3098872\/423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T14:13:00Z","timestamp":1673100780000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/2\/5\/423\/665839\/Bispecific-Antibodies-in-Multiple-Myeloma-Present"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":99,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,17]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0028","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}